New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear.

BACKGROUND AND OBJECTIVES A relation between the size of treatment efficacy and severity of the disease has been postulated and observed as linear for a few therapies. We have called this relation the effect model. Our objectives were to demonstrate that the relation is general and not necessarily linear. STUDY DESIGN AND SETTING We extend the number of observed effect model. Then we established three numerical models of treatment activity corresponding to the three modes of action we have identified. Using these models, we simulated the relation. RESULTS Empirical evidence confirms the effect model and suggests that it may be linear over a short range of event frequency. However, it provides an incomplete understanding of the phenomenon because of the inescapable limitations of data from randomized clinical trials. Numerical modeling and simulation show that the real effect model is likely to be more complicated. It is probably linear only in rare instances. The effect model is general. It depends on factors related to the individual, disease and outcome. CONCLUSION Contrarily to common, assumption, since the effect model is often curvilinear, the relative risk cannot be granted as constant. The effect model should be taken into account when discovering and developing new therapies, when making, health care policy decisions or adjusting clinical decisions to the patient risk profile.

[1]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[2]  Douglas G Altman,et al.  The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.

[3]  J. Collet,et al.  An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.

[4]  Sylvie Chabaud,et al.  Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  T Stijnen,et al.  Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. , 2000, Statistics in medicine.

[6]  D E Grobbee,et al.  Does drug treatment improve survival? Reconciling the trials in mild‐to-moderate hypertension , 1995, Journal of hypertension.

[7]  François Gueyffier,et al.  Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems , 2003, Clinical chemistry and laboratory medicine.

[8]  S. Senn Individual response to treatment: is it a valid assumption? , 2004, BMJ : British Medical Journal.

[9]  I. Wiklund,et al.  Physical inactivity as a risk factor for primary and secondary coronary events in Göteborg, Sweden. , 1988, European heart journal.

[10]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[11]  M. McIntosh,et al.  The population risk as an explanatory variable in research synthesis of clinical trials. , 1996, Statistics in medicine.

[12]  J. Boissel,et al.  Revisiting the effect compartment through timing errors in drug administration. , 1998, Trends in pharmacological sciences.

[13]  J. Boissel,et al.  Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. , 1990, The American journal of cardiology.

[14]  Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists” , 1995 .

[15]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[16]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[17]  J. Boissel Individualizing aspirin therapy for prevention of cardiovascular events. , 1998, JAMA.

[18]  Les M Irwig,et al.  An evidence based approach to individualising treatment , 1995, BMJ.

[19]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[20]  L. Aarons,et al.  Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Karla Kerlikowske,et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.

[22]  L Aarons,et al.  A pharmacokinetic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.